Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

Collaboration and License Revenue: Collaboration and license revenue for the third quarter ended September 30, 2024 was $10.0 million, as compared to zero for the same period in 2023. The increase was ...

The APEX abstract in advanced systemic mastocytosis, or ASM, disclosed one incremental patient discontinuation due to ALT/AST elevation, but the firm notes the 28% rate of ALT/AST increase continues ...